AIFMD Consultation: Beyond the Headlines

October 26, 2020


We have been covering the ongoing review of the Alternative Investment Fund Managers Directive (AIFMD) for some time now. Last week, the European Commission (EC) released its public consultation which the industry is currently parsing. The consultation questions are largely consistent with issues highlighted by the ESMA letter sent to the Commission in August. Certain issues have grabbed the headlines, while other items might not grab headlines but remain important. Let’s look at both: 

Headline Grabbers

Not unusually, most initial industry attention and market commentary has focused on the thorny issues of delegation to non-EU based entities, and the ever-increasing likelihood that so called third country passports for managers based outside the EU will not be forthcoming. The consultation paper asks whether the use of national placement regimes for non-EU managers, which allows them to sell in individual EU countries, creates an “uneven playing field” between EU and non-EU fund managers. This indicates that rather than an extension of third country passports, further curbs on non-EU managers selling into Europe is the likelier outcome. 

The delegation point is particularly key since it’s a central pillar of most global investment managers model. For asset managers, it is common practice to base themselves and sell funds in the EU, while at the same time outsource certain investment decisions or other tasks to financial centers such as the UK or United States where the expertise resides. This dispersed global model is increasingly challenged by a focus on increased substance and activity to be conducted within the EU’s borders. AIFMD also already contains specific rules to govern such delegation; however, the consultation questions whether the rules should go further and be more specific. The consultation asks whether prescribing “quantitative” maximum limits on delegation or a list of “core or critical functions” that should be performed in the EU is necessary.

It is rightly a crucial area of focus for global asset managers who look to leverage global resource and expertise to best serve their European client base. It’s also, however, an issue heavily entwined in the wider Brexit negotiations, and will essentially be dictated by how that saga ends.

Delegation is an issue which more parochially has reared its head very recently in Ireland, where the Central Bank of Ireland released its findings in relation to its thematic review (CP86) of fund management companies (FMC). Again, one of the central themes was whether the local Irish fund management company displayed thorough enough scrutiny of non-Irish delegates in terms of due diligence, ongoing supervision, and independent challenge of the foreign delegate by the Irish FMC

Three Sleeper Issues

There are host of issues addressed within the consultation which is not unusual given AIFMD was one of the most widespread and all-encompassing regulatory implementations imposed after the great financial crisis. Among these are issues that have nothing to do with the “international relations” but rather might have a sizeable impact on EU AIFMs operating within the current regime. What follows are three issues worth exploring:

ESMA’s Wider Remit

Some years ago, ESMA’s changed its terms of reference and they were given certain “superpowers” to directly supervise the EU markets. The main aim was to increase regulatory harmonization in instances where multiple national regimes might be sub-optimal for supervision. Recently, ESMA has increasingly begun to use its overarching powers to conduct EU-wide market assessments itself, rather than delegate such reviews to national competent authorities (NCAs).

An example is a Common Supervisory Action (CSA) where ESMA sets the questions, then requests the NCAs in member states collect responses and data from regulated entities under their supervision and provide them back to ESMA for their review. As a result, this means consistency of approach and uniformity of data which ultimately leads to more consistent implementation and application of EU rules. ESMA has already conducted CSAs on fund liquidity this year and will do so once more in 2021, while they have also flagged an upcoming assessment of costs and fees using the same mechanism. ESMA’s direct supervision mandate appears to increase year-on-year.

Once more within the AIFMD review the concept of ESMA taking a more central role in pan-EU supervision is raised in several ways within the CP. There is a suggestion that ESMA be given “strong and binding coordination powers in market stress situations” so they have a single view at a time where systemic risk might increase across the EU. There is also suggestion that AIFMD reporting be centralized with ESMA rather than submitted to NCAs and also that ESMA be given powers to take action against individual AIMFs and AIFs where their activities threaten integrity of the EU financial market or stability the financial system.

What is certain is that ESMA appear to have a desire to be more rather than less involved in direct supervision of the EU market. What this means for national regulators and for asset managers operating in Europe is less certain but remains an area worth monitoring.

Depositary Issues

One of the biggest shifts that occurred due to the original AIFMD implementation was the amplification of the importance of the fund depositary as it relates to asset safekeeping and investor protection. The role of a fund depositary is now seen as an essential oversight function for all EU regulated funds, but it wasn’t always so.

The consultation asks in broad strokes what difficulties depositaries have faced in exercising their duties under AIFMD. It then drills into some very technical but very important asset safekeeping and other depositary related topics, such as:

  • Tri-party collateral management 
  • Prime broker reporting
  • International central securities depositaries (iCSDs) as delegates  

It also raises the issue of an AIFMD depositary passport. Currently, the appointed depositary must be located in the domicile of the AIF fund. The two dominant AIFMD domiciles are Ireland and Luxembourg and as such this is where the largest most experienced depositaries reside. A depositary passport opens up the possibility that an authorized depositary could provide oversight of AIF funds in other EU domiciles. For instance, an Irish or Luxembourg depositary might be appointed to a Polish AIFMD fund. One of the drivers of the concept is that some smaller EU AIFMD markets are not well served with local depositaries and a depositary passport could address the lack of supply of depositary services in smaller EU markets.

There are pros, cons, and complex legal considerations when it comes to each of these depositary considerations.  These are issues that exercise BBH as a matter of course but they are also consequential to asset managers operating under AIFMD and as such we are also happy to discuss the gory details as required.

Fund Valuation

AIFMD imposes very specific asset valuation provisions in order to ensure investors can have confidence that the value of their investment is accurate, and if they redeem the value of their redemption proceeds can reasonably be assured. AIFMD fund assets are either valued “internally” by the asset managers or by an external valuer, an entity totally independent of the AIFM. It’s currently an either/or scenario and a mixture of the two models is not possible.

Also, external valuer liability standards are quite strict, which results in certain reluctance by some agents to act in this capacity or ones who do to charge premium pricing to cover their liability risk.  The CP therefore poses the question whether the liability provisions are too onerous and should be reduced in order to tempt more providers into the space increasing choice and reducing costs in a classic supply & demand market dynamic.

If amended, this, in theory, would be a very beneficial change to all stakeholders. But asset managers who often must reluctantly take on this valuation liability even though they still utilize third party entities to value the asset. Further, any cost efficiencies that can be brought to bear currently are most welcome in a very competitive market and another area of intense regulatory focus.

These are each important issues in their own right, but an exhaustive list of all issues covered in the CP. There are several other important issues not covered here but that have material impact on managers operating or thinking of operating under the AFMD regime in the future.  With the consultation running until January 29, 2021 we are sure to be hearing plenty more about AIFMD from now until then.

Brown Brothers Harriman & Co. (“BBH”) may be used as a generic term to reference the company as a whole and/or its various subsidiaries generally. This material and any products or services may be issued or provided in multiple jurisdictions by duly authorized and regulated subsidiaries.This material is for general information and reference purposes only and does not constitute legal, tax or investment advice and is not intended as an offer to sell, or a solicitation to buy securities, services or investment products. Any reference to tax matters is not intended to be used, and may not be used, for purposes of avoiding penalties under the U.S. Internal Revenue Code, or other applicable tax regimes, or for promotion, marketing or recommendation to third parties. All information has been obtained from sources believed to be reliable, but accuracy is not guaranteed, and reliance should not be placed on the information presented. This material may not be reproduced, copied or transmitted, or any of the content disclosed to third parties, without the permission of BBH. All trademarks and service marks included are the property of BBH or their respective owners.© Brown Brothers Harriman & Co. 2021. All rights reserved.

This browser is not fully supported by our public website and may not display or function as expected for this reason. Please note, the Infuse Portal and BBH client applications fully support the IE 11 browser.

Important Information for Non-U.S. Residents

You are required to read the following important information, which, in conjunction with the Terms and Conditions, governs your use of this website. Your use of this website and its contents constitute your acceptance of this information and those Terms and Conditions. If you do not agree with this information and the Terms and Conditions, you should immediately cease use of this website. The contents of this website have not been prepared for the benefit of investors outside of the United States. This website is not intended as a solicitation of the purchase or sale of any security or other financial instrument or any investment management services for any investor who resides in a jurisdiction other than the United States1. As a general matter, Brown Brothers Harriman & Co. and its subsidiaries (“BBH”) is not licensed or registered to solicit prospective investors and offer investment advisory services in jurisdictions outside of the United States. The information on this website is not intended to be distributed to, directed at or used by any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Persons in respect of whom such prohibitions apply must not access the website.  Under certain circumstances, BBH may provide services to investors located outside of the United States in accordance with applicable law. The conditions under which such services may be provided will be analyzed on a case-by-case basis by BBH. BBH will only accept investors from such jurisdictions or countries where it has made a determination that such an arrangement or relationship is permissible under the laws of that jurisdiction or country. The existence of this website is not intended to be a substitute for the type of analysis described above and is not intended as a solicitation of or recommendation to any prospective investor, including those located outside of the United States. Certain BBH products or services may not be available in certain jurisdictions. By choosing to access this website from any location other than the United States, you accept full responsibility for compliance with all local laws. The website contains content that has been obtained from sources that BBH believes to be reliable as of the date presented; however, BBH cannot guarantee the accuracy of such content, assure its completeness, or warrant that such information will not be changed. The content contained herein is current as of the date of issuance and is subject to change without notice. The website’s content does not constitute investment advice and should not be used as the basis for any investment decision. There is no guarantee that any investment objectives, expectations, targets described in this website or the  performance or profitability of any investment will be achieved. You understand that investing in securities and other financial instruments involves risks that may affect the value of the securities and may result in losses, including the potential loss of the principal invested, and you assume and are able to bear all such risks.  In no event shall BBH or any other affiliated party be liable for any direct, incidental, special, consequential, indirect, lost profits, loss of business or data, or punitive damages arising out of your use of this website. By clicking accept, you confirm that you accept  to the above Important Information along with Terms and Conditions.

 
1BBH sponsors UCITS Funds registered in Luxembourg, in certain jurisdictions. For information on those funds, please see bbhluxembourgfunds.com


captcha image

Type in the word seen on the picture

I am a current investor in another jurisdiction